Haleon (LON:HLN - Free Report) had its target price trimmed by Barclays from GBX 390 ($4.94) to GBX 383 ($4.85) in a report published on Tuesday morning, LSE.Co.UK reports. The brokerage currently has an overweight rating on the stock.
Haleon Stock Performance
Shares of HLN traded up GBX 0.70 ($0.01) during trading hours on Tuesday, hitting GBX 322.30 ($4.08). The company had a trading volume of 13,306,663 shares, compared to its average volume of 18,909,568. The firm has a market cap of £29.43 billion and a price-to-earnings ratio of 2,919.09. The business has a fifty day moving average of GBX 324.78 and a 200-day moving average of GBX 327.34. Haleon has a 12 month low of GBX 306.80 ($3.88) and a 12 month high of GBX 357.65 ($4.53). The company has a quick ratio of 0.93, a current ratio of 1.04 and a debt-to-equity ratio of 57.42.
Haleon Increases Dividend
The firm also recently declared a dividend, which will be paid on Thursday, May 16th. Investors of record on Thursday, March 14th will be paid a GBX 4.20 ($0.05) dividend. The ex-dividend date is Thursday, March 14th. This is an increase from Haleon's previous dividend of $1.80. This represents a dividend yield of 1.34%. Haleon's dividend payout ratio is 5,454.55%.
Insider Activity at Haleon
In other Haleon news, insider Tobias Hestler sold 23,564 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of GBX 329 ($4.16), for a total transaction of £77,525.56 ($98,121.20). 22.53% of the stock is currently owned by corporate insiders.
Haleon Company Profile
(
Get Free Report)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Read More
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
